Figure 6a and b shows that treatment of mice bearing subcutaneously implanted RMA-S tumors with Clec9a antibody co-targeted TAP siRNA and CpG ODN (Clec-CpG/Tap) was more effective than treatment with Clec9a targeted TAP siRNA and CD40 antibody (Clec-Tap + CD40) and was dependent on co-delivery of the TAP siRNA and CpG ODN to the same cell because treatment with a mixture of Cle9a targeted TAP siRNA and Cle9a targeted CpG ODN (Clec-Tap siRNA + Clec-CpG) did not inhibit tumor growth. This evidence concerns the gene CD40 and neoplasm.